Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01083602Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in multiple myeloma (MM), sponsored by Novartis. Started Jun 2010; status: completed.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01083602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01083602.